Explore

AP News AP News
Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiative

Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiative

President Donald Trump has announced a deal with Regeneron to lower the cost of its pharmaceutical products
Reuters Reuters
White House to announce drug pricing deal with Regeneron

White House to announce drug pricing deal with Regeneron

By Sriparna Roy WASHINGTON, April 23 (Reuters) - The White House will announce a drug pricing deal with Regeneron Pharmaceuticals at an event on Thursday afternoon, White House press ⁠secretary Karoline Leavitt said in a post on X.
Trendline Trendline
President Trump Announces Regeneron Deal to Lower Drug Prices for American Patients

President Trump Announces Regeneron Deal to Lower Drug Prices for American Patients

President Trump Announces Regeneron Deal to Lower Drug Prices for American Patients
Rapid Read Rapid Read
President Trump Announces Regeneron Deal to Lower Drug Prices for Medicaid

President Trump Announces Regeneron Deal to Lower Drug Prices for Medicaid

President Donald Trump is set to announce a deal with Regeneron Pharmaceuticals to lower the cost of its drugs as part of the White House's most-favored-nation drug pricing initiative. The agreement includes reducing prices for current and future drugs on Medicaid and selling the cholesterol drug Praluent for $225 on the TrumpRx website. This initiative is part of the Trump administration's efforts to provide economic relief amid rising costs for healthcare and other essentials. The deal with Regeneron is the final agreement in a series of negotiations with major pharmaceutical companies aimed at aligning U.S. drug prices with those in other developed nations. Additionally, Regeneron has committed to investing nearly $10 billion to bring pharmaceutical production to the U.S., which aligns with Trump's strategy of offering tariff relief in exchange for domestic production commitments.
AP News AP News
Trump will unveil a deal with Regeneron to lower drug prices

Trump will unveil a deal with Regeneron to lower drug prices

President Donald Trump is set to announce a deal with Regeneron to lower drug costs as part of the White House's effort to lower drug prices
Reuters Reuters
Europe risks falling further behind in medicine race, warns Roche CEO

Europe risks falling further behind in medicine race, warns Roche CEO

By Maggie Fick and Bhanvi Satija BARCELONA, April 23 (Reuters) - Europe risks falling further behind the United States and China in pharmaceutical research and innovation because of "mind-blowing" bureaucracy and government policies threatening jobs, Roche Chief Executive Thomas Schinecker warned on
Trendline Trendline
Mark Cuban Urges Congress to Break Up Pharmacy Benefit Managers for Market Efficiency

Mark Cuban Urges Congress to Break Up Pharmacy Benefit Managers for Market Efficiency

Mark Cuban Urges Congress to Break Up Pharmacy Benefit Managers for Market Efficiency
Rapid Read Rapid Read
FDA Approves Regeneron's Otarmeni as First Gene Therapy for Genetic Hearing Loss

FDA Approves Regeneron's Otarmeni as First Gene Therapy for Genetic Hearing Loss

Regeneron Pharmaceuticals has received FDA approval for Otarmeni, a gene therapy designed to treat severe-to-profound sensorineural hearing loss associated with the OTOF gene. This approval is based on the CHORD trial, which demonstrated significant hearing improvements in participants. Otarmeni is the first gene therapy to restore neurosensory function to normal levels and will be provided for free in the U.S. by Regeneron. The therapy uses an adeno-associated virus vector to deliver a working copy of the OTOF gene, aiming to restore natural hearing in affected individuals.
AP News AP News
'Two ways of calculating': Trump defends his mathematically impossible calculations on drug prices

'Two ways of calculating': Trump defends his mathematically impossible calculations on drug prices

President Donald Trump, known for popularizing the term "fake news," seems to have shifted focus to a healthy dose of fake math in defending impossibly large cuts to prescription drug prices
AP News AP News
RFK Jr. goes before the Senate. One lawmaker's competing loyalties will be on display

RFK Jr. goes before the Senate. One lawmaker's competing loyalties will be on display

Sen. Bill Cassidy faces a tough situation as he prepares to question Robert F. Kennedy Jr. in two Senate hearings
Trendline Trendline
Regeneron Receives FDA Approval for Otarmeni, First Gene Therapy for Genetic Hearing Loss, Offered Free in U.S.

Regeneron Receives FDA Approval for Otarmeni, First Gene Therapy for Genetic Hearing Loss, Offered Free in U.S.

Regeneron Receives FDA Approval for Otarmeni, First Gene Therapy for Genetic Hearing Loss, Offered Free in U.S.
Reuters Reuters
Germany risks missing out on new drugs, AstraZeneca CEO tells paper

Germany risks missing out on new drugs, AstraZeneca CEO tells paper

FRANKFURT, April 21 (Reuters) - AstraZeneca's CEO told daily Handelsblatt on Tuesday that Germany risks missing out on new drugs that the Anglo-Swedish drugmaker plans to launch if the nation sticks with plans to keep spending on pharmaceuticals in check.